China Pharma Univ. CDC20 compound E1

China Pharma Univ. CDC20 compound E1: sourced facts only. name: "Furthermore, compound E1 specifically targeted CDC20 and exhibited a higher binding affinity to CDC20 compared to that of Apcin, thereby inducing cell cycle arrest in the G2/M phase of cancer cells." [PMID:38364716]; target: "Furthermore, compound E1 specifically targeted CDC20 and exhibited a higher binding affinity to CDC20 compared to that of Apcin, thereby inducing cell cycle arrest in the G2/M phase of cancer cells." [PMID:38364716]; developer: "Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, China." [PMID:38364716]; stage: "In 4T1 Xenograft Models compound E1 exhibited the potential antitumor activity without obvious toxicity." [PMID:38364716]